Vivos (RDGL) 10-Q 25 Oct 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Oct. 25, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-53497
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Entity Tax Identification Number	80-0138937
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	719 Jadwin Avenue
Entity Address, City or Town	Richland
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99352
City Area Code	(509)
Local Phone Number	736-4000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		337,781,082

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 1,986,591	$ 903,704
Accounts receivable	8,887
Prepaid expenses	48,315	33,835
Total Current Assets	2,043,793	937,539
TOTAL ASSETS	2,043,793	937,539
Current Liabilities:
Accounts payable and accrued expenses	172,652	361,880
Related party accounts payable	32,110	32,110
Accrued interest payable	118,869	100,954
Payroll liabilities payable		66,143
Convertible notes payable, net	58,761	107,418
Related party promissory note	237,000	237,000
Total Current Liabilities	619,392	905,505
Total Liabilities	619,392	905,505
Commitments and contingencies
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock, par value, $0.001, 950,000,000 shares authorized, 335,775,389 and 292,278,591 issued and outstanding, respectively	335,775	292,279
Additional paid in capital - common stock	68,265,171	64,551,764
Subscription receivable
Accumulated deficit	(76,907,637)	(74,558,101)
Total Stockholders’ Equity (Deficit)	1,424,401	32,034
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	2,043,793	937,539
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, value	2,071	2,171
Additional paid in capital	8,842,458	8,857,358
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, value	436	436
Additional paid in capital	385,235	385,235
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, value	385	385
Additional paid in capital	$ 500,507	$ 500,507

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	335,775,389	292,278,591
Common stock, shares outstanding	335,775,389	292,278,591
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,071,007	2,171,007
Preferred stock, shares outstanding	2,071,007	2,171,007
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	436,653	436,653
Preferred stock, shares outstanding	436,653	436,653
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	385,302	385,302
Preferred stock, shares outstanding	385,302	385,302

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Consulting revenues, net	$ 14,887	$ 7,000	$ 14,887	$ 7,000
OPERATING EXPENSES
Professional fees	55,583	59,502	172,028	170,771
Stock based compensation			1,614,000	2,176
Payroll expenses	64,925	34,029	202,428	94,029
Research and development	66,831	14,383	227,154	31,809
General and administrative expenses	22,131	27,526	82,635	85,482
Total Operating Expenses	209,470	135,440	2,298,245	384,267
OPERATING LOSS	(194,583)	(128,440)	(2,283,358)	(377,267)
NON-OPERATING INCOME (EXPENSE)
Interest expense	(6,577)	(7,151)	(19,628)	(280,642)
Other income				3,000
Forgiveness of debt			129,745
Loss on debt extinguishment			(176,295)
Total Non-Operating Income (Expenses)	(6,577)	(7,151)	(66,178)	(277,642)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(201,160)	(135,591)	(2,349,536)	(654,909)
Provision for income taxes
NET LOSS	$ (201,160)	$ (135,591)	$ (2,349,536)	$ (654,909)
Net loss per share - basic and diluted	$ 0	$ 0	$ (0.01)	$ 0
Weighted average common shares outstanding - basic and diluted	335,506,200	234,418,486	321,548,977	213,424,420

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred [Member]	Additional Paid-In Capital - Series A Preferred [Member]	Series B Preferred [Member]	Additional Paid-In Capital - Series B Preferred [Member]	Series C Preferred [Member]	Additional Paid-In Capital - Series C Preferred [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	(Subscription Receivable) / Shares to be Issued [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2019	$ 2,553	$ 8,870,626	$ 1,113	$ 665,195	$ 821	$ 674,457	$ 184,846	$ 61,721,809		$ (73,601,109)	$ (1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821
Cash									6,870		6,870
Note conversions/settlements									526,113		526,113
Redemption of preferred stock in convertible note agreement			$ (100)	(49,900)							(50,000)
Redemption of preferred stock in convertible note agreement,shares			(100,000)
Conversion of preferred stock into common stock					$ (436)	(173,950)	$ 5,449	168,937
Conversion of preferred stock into common stock,shares					(435,990)		5,449,875
Warrants issued with notes payable (discount)								28,482			28,482
Options and warrants issued for services								77,883			77,883
Share adjustment
Share adjustment, shares							(62)
Net loss for the period										(360,231)	(360,231)
Ending balance at Mar. 31, 2020	$ 2,553	8,870,626	$ 1,013	615,295	$ 385	500,507	$ 190,295	61,997,111	532,983	(73,961,340)	(1,250,572)
Balance, shares at Mar. 31, 2020	2,552,642		1,013,245		385,302		190,295,634
Beginning balance at Dec. 31, 2019	$ 2,553	8,870,626	$ 1,113	665,195	$ 821	674,457	$ 184,846	61,721,809		(73,601,109)	(1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821
Net loss for the period											(654,909)
Ending balance at Sep. 30, 2020	$ 2,553	8,870,626	$ 1,013	615,295	$ 385	500,507	$ 234,700	63,160,706		(74,256,018)	(870,233)
Balance, shares at Sep. 30, 2020	2,552,642		1,013,245		385,302		234,700,228
Beginning balance at Dec. 31, 2019	$ 2,553	8,870,626	$ 1,113	665,195	$ 821	674,457	$ 184,846	61,721,809		(73,601,109)	(1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821
Ending balance at Dec. 31, 2020	$ 2,171	8,857,358	$ 436	385,235	$ 385	500,507	$ 292,279	64,551,764		(74,558,101)	32,034
Balance, shares at Dec. 31, 2020	2,171,007		436,653		385,302		292,278,591
Beginning balance at Mar. 31, 2020	$ 2,553	8,870,626	$ 1,013	615,295	$ 385	500,507	$ 190,295	61,997,111	532,983	(73,961,340)	(1,250,572)
Balance, shares at Mar. 31, 2020	2,552,642		1,013,245		385,302		190,295,634
Cash							$ 18,440	479,440	(6,870)		491,010
Cash,shares							18,440,000
Note conversions/settlements							$ 24,113	626,931	(526,113)		124,931
Note conversions/settlements, shares							24,112,742
Options and warrants issued for services								2,176			2,176
Net loss for the period										(159,087)	(159,087)
Warrants purchased for cash								6,900			6,900
Ending balance at Jun. 30, 2020	$ 2,553	8,870,626	$ 1,013	615,295	$ 385	500,507	$ 232,848	63,112,558		(74,120,427)	(784,642)
Balance, shares at Jun. 30, 2020	2,552,642		1,013,245		385,302		232,848,376
Note conversions/settlements							$ 1,852	48,148			50,000
Note conversions/settlements, shares							1,851,852
Net loss for the period										(135,591)	(135,591)
Ending balance at Sep. 30, 2020	$ 2,553	8,870,626	$ 1,013	615,295	$ 385	500,507	$ 234,700	63,160,706		(74,256,018)	(870,233)
Balance, shares at Sep. 30, 2020	2,552,642		1,013,245		385,302		234,700,228
Beginning balance at Dec. 31, 2020	$ 2,171	8,857,358	$ 436	385,235	$ 385	500,507	$ 292,279	64,551,764		(74,558,101)	32,034
Balance, shares at Dec. 31, 2020	2,171,007		436,653		385,302		292,278,591
Cash							$ 22,500	1,777,500			1,800,000
Cash,shares							22,500,000
Note conversions/settlements							$ 1,259	225,406			226,665
Note conversions/settlements, shares							1,259,250
Accounts payable							$ 384	49,616			50,000
Accounts payable, shares							384,445
Warrant exercises							$ 3,870	(3,870)
Warrant exercises, shares							3,870,428
Net loss for the period										(288,189)	(288,189)
Warrants purchased for cash								11,238			11,238
Ending balance at Mar. 31, 2021	$ 2,171	8,857,358	$ 436	385,235	$ 385	500,507	$ 320,292	66,611,654		(74,846,290)	1,831,748
Balance, shares at Mar. 31, 2021	2,171,007		436,653		385,302		320,292,714
Beginning balance at Dec. 31, 2020	$ 2,171	8,857,358	$ 436	385,235	$ 385	500,507	$ 292,279	64,551,764		(74,558,101)	32,034
Balance, shares at Dec. 31, 2020	2,171,007		436,653		385,302		292,278,591
Net loss for the period											(2,349,536)
Ending balance at Sep. 30, 2021	$ 2,071	8,842,458	$ 436	385,235	$ 385	500,507	$ 335,775	68,265,171		(76,907,637)	$ 1,424,401
Balance, shares at Sep. 30, 2021	2,071,007		436,653		385,302		335,775,389
Stock option exercises, shares											2,500,000
Beginning balance at Mar. 31, 2021	$ 2,171	8,857,358	$ 436	385,235	$ 385	500,507	$ 320,292	66,611,654		(74,846,290)	$ 1,831,748
Balance, shares at Mar. 31, 2021	2,171,007		436,653		385,302		320,292,714
Accounts payable							$ 520	39,480			40,000
Accounts payable, shares							519,480
RSUs							$ 12,000	(12,000)
RSUs, shares							12,000,000
Stock option exercises	$ (100)	(14,900)					$ 2,125	12,875
Stock option exercises, shares	(100,000)
RSU’s granted to consultants that have vested								1,614,000			1,614,000
Net loss for the period										(1,860,187)	(1,860,187)
Ending balance at Jun. 30, 2021	$ 2,071	8,842,458	$ 436	385,235	$ 385	500,507	$ 334,937	68,266,009		(76,706,477)	1,625,561
Balance, shares at Jun. 30, 2021	2,071,007		436,653		385,302		334,937,194
Stock option exercises, shares							2,125,000
Warrant exercises							$ 838	(838)
Warrant exercises, shares							838,195
Net loss for the period										(201,160)	(201,160)
Ending balance at Sep. 30, 2021	$ 2,071	$ 8,842,458	$ 436	$ 385,235	$ 385	$ 500,507	$ 335,775	$ 68,265,171		$ (76,907,637)	$ 1,424,401
Balance, shares at Sep. 30, 2021	2,071,007		436,653		385,302		335,775,389

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOW FROM OPERTING ACTIVIITES
Net loss	$ (2,349,536)	$ (654,909)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of convertible debt discount		53,527
Amortization of BCF discount		6,187
Stock options and warrants for services		2,176
RSUs issued for services	1,614,000
Loss on conversion of debt	176,295
Forgiveness of debt	(129,745)
Warrants issued for interest expense		77,883
Exchange premium in conversion of notes		98,508
Changes in assets and liabilities
Accounts receivable	(8,887)
Prepaid expenses and other assets	(14,480)	(19,477)
Accounts payable and accrued expenses	30,517	(134,334)
Accounts payable and accrued expenses from related party
Payroll liabilities	(66,143)	30,000
Accrued interest	19,628	30,212
Total adjustments	1,621,185	144,682
Net cash used in operating activities	(728,351)	(510,227)
CASH FLOWS FROM FINANCING ACTIVITES
Redemption of preferred stock		(50,000)
Proceeds from sale of common stock and warrants	1,811,238	504,780
Proceeds from convertible debt		100,000
Payment of note payable		(50,000)
Net cash provided by financing activities	1,811,238	504,780
NET INCREASE (DECREASE) IN CASH	1,082,887	(5,447)
CASH - BEGINNING OF PERIOD	903,704	20,381
CASH - END OF PERIOD	1,986,591	14,934
CASH PAID DURING THE PERIOD FOR:
Interest expense		13,442
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of preferred stock into common stock		174,386
Recognition of debt discount at inception of notes payable		28,482
Conversion of notes payable and accrued interest into common stock	50,370	701,044
Common stock issued in cashless exercise of warrants	4,708
RSUs vested into common stock	12,000
Accounts payable converted into shares of common stock	90,000
Stock options exercised for recission of common and preferred stock	$ 60,000

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES The accompanying condensed financial statements of Vivos Inc. (the “ Company Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“ SMSC 950,000,000 0.001 20,000,000 0.001 Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel ™ In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™ FDA ® Based on the FDA’s recommendation, RadioGel ™ ® ® ® ™ ® ™ ® ™” ® ® IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet ® ® The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet ® ® The effectiveness of IsoPet ® ® The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel ™ ® ® Commencing in July 2019, the Company recognized its first commercial sale of IsoPet ® ® Our plan is to incorporate the data assembled from our work with Isopet ® ™ FDA ™ ™ ™ Y-90 half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days Recently, the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication. The Company’s lead brachytherapy products, including RadioGel ™ Battelle ™ Battelle License The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet ® ™ Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $ 2 The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019. The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 0.10 5,000,000 The Company’s initial Regulation A+ raised approximately $ 4,000,000 For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents. ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist new regional clinics with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $ 2 the next 12 to 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel ™ Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States, the initial epicenter of the COVID-19 outbreak in the United States. The Company has started to in recent weeks to continue their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. As of September 30, 2021, the Company has $ 1,986,591 There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2021 and December 31, 2020, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis. Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $ 2,500 1,500 Depreciation is computed using the straight-line method over the following estimated useful lives: SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE Production equipment: 3 7 Office equipment: 2 5 Furniture and fixtures: 2 5 Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel ™ 17,500 the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%) Future minimum royalties for the years ending December 31 are noted below: SCHEDULE OF FUTURE MINIMUM ROYALTIES Sep 30, 2021 Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2021 fee was paid in December 2020. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10 The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the nine months ended September 30, 2021 or years ended December 31, 2020 and 2019, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet ® Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue recognized in the nine months ended September 30, 2021 and 2020 relate to consulting income with respect to the IsoPet ® Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2021 and 2020, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of September 30, 2021 and December 31, 2020, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE September 30, 2021 December 31, 2020 Convertible debt 2,492 1,252,456 Preferred stock 12,863,195 12,988,195 Common stock options 2,252,809 28,885,461 Common stock warrants 35,362,500 32,064,375 Total potential dilutive securities 50,480,996 75,190,487 Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $ 227,154 31,809 Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the nine months ended September 30, 2021 and 2020, the Company incurred no Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2021 and December 31, 2020. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine months ended September 30, 2021 and 2020. The Company did not have any deferred tax liability or asset on its balance sheet on September 30, 2021 and December 31, 2020. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine months ended September 30, 2021 and 2020, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment. Recent Accounting Pronouncements In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 2: RELATED PARTY TRANSACTIONS Related Party Convertible Notes Payable The Company from time to time receives non-interest bearing advancers from its Chief Executive Officer that are due on demand. During the year ended December 31, 2019, the Company received $ 20,000 5,000 15,000 8 January 15, 2020 321 150,000 The Company recognized a discount on the convertible note of $ 3,721 12.5 Interest expense for the nine months ended September 30, 2021 and 2020 on the related party convertible notes payable amounted to $ 0 298 Related Party Notes Payable As of September 30, 2021 and December 31, 2020, the Company had the following related party notes outstanding: SCHEDULE OF RELATED PARTY TRANSACTION September 30, 2021 December 31, 2020 January 2019 $ 60,000 8 January 2020 $ 60,000 $ 60,000 March 2019 $ 48,000 8 March 2020 48,000 48,000 April 2019 $ 29,000 8 April 2020 29,000 29,000 July 2019 $ 50,000 8 July 2020 50,000 50,000 November 2019 $ 50,000 8 November 2020 50,000 50,000 Total Related Party Notes Payable, Net $ 237,000 $ 237,000 On January 24, 2019 the Company entered into a note payable with a trust related to one of the Company’s directors in the amount of $ 60,000 one January 24, 2020 8.00 On March 27, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $ 48,000 one-year period March 27, 2020 8 29,000 50,000 one-year period July 5, 2020 8 50,000 one-year period November 25, 2020 8 14,142 14,194 44,409 The Company borrowed $ 15,000 Related Party Payables The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $ 32,110 32,110 Preferred and Common Shares Issued to Officers and Directors The Company’s Chairman converted the Series B Convertible Preferred Shares into Series C Convertible Preferred Shares and as of April 2020, the 385,302 In April 2020, effective March 31, 2020, the Company converted the $ 15,000 619 3,124 694,178 The Company’s Chief Executive Officer exercised 2,500,000 60,000 2,500,000 60,000 375,000 100,000 8,120,152 16,000,000 150,000 91,304

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 3: CONVERTIBLE NOTES PAYABLE As of September 30, 2021 and December 31, 2020, the Company had the following convertible notes outstanding. All prior notes that have been converted into common stock or repaid prior to December 31, 2020 have been excluded from the chart: SCHEDULE OF CONVERTIBLE NOTES PAYABLE 2021 2020 July and August 2012 $ 1,060,000 4.60 12 December 2013 January 2014 $ 45,000 $ 45,000 November 2020 $ 50,000 0.04 6 May 30, 2021 - 50,000 Penalties on notes in default 13,761 12,418 $ 58,761 $ 107,418 The Company entered into a $ 50,000 May 30, 2021 6 0.04 350,000 1.20 1,867,500 933,750 Interest expense for the nine months ended September 30, 2021 and 2020 on the convertible notes payable amounted to $ 4,028 19,783

PROMISSORY NOTES PAYABLE

PROMISSORY NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Promissory Notes Payable
PROMISSORY NOTES PAYABLE	NOTE 4: PROMISSORY NOTES PAYABLE The Company issued two separate promissory notes on February 20, 2019 at $ 50,000 100,000 August 20, 2019 8.00 1,250,000 28,721 On August 20, 2019, the two noteholders agreed to extend these notes another six-months to February 20, 2020, then amended again for six-months and the notes were to mature August 20, 2020 750,000 375,000 8 15 The interest expense on these notes for the nine months ended September 30, 2021 and 2020 amounted to $ 0 8,032 The Company repaid $ 50,000 13,442 50,000 1,851,852

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 5: STOCKHOLDERS’ DEFICIT Common Stock The Company has 950,000,000 0.001 335,775,389 292,278,591 On March 28, 2019, the Company’s board of directors approved a reverse 1-for-8 stock split 2,000,000,000 950,000,000 Preferred Stock As of September 30, 2021 and December 31, 2020, the Company has 20,000,000 0.001 On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $ 0.001 5,000,000 On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $ 0.001 5,000,000 Series A Convertible Preferred Stock (“Series A Convertible Preferred”) In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 2,500,000 5,000,000 Liquidation Preference 5.00 Dividends Conversion Series A Conversion Shares 4.00 In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $ 5 Redemption Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100 Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization In June 2021, 100,000 Series B Convertible Preferred Stock (“Series B Convertible Preferred”) In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5 Liquidation Preference 1.00 Dividends Conversion Series B Conversion Shares 0.08 Redemption Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100 Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series C Convertible Preferred Stock (“Series C Convertible Preferred”) In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5 Liquidation Preference 1.00 Dividends Conversion Series C Conversion Shares 0.08 The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“ Authorized Share Approval Initial Convertibility Date Conversion Rights Redemption Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100 Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Common and Preferred Stock Issuances - 2021 In January 2021, the Company issued 384,445 50,000 519,480 40,000 In January 2021, the Company issued 1,259,250 50,370 176,295 In March 2021, the Company issued 22,500,000 11,237,500 1,800,000 11,238 Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 5,430,000 On June 28, 2021, the Company issued 2,500,000 2,500,000 375,000 In June 2021, the Company issued 12,000,000 1,080,000 From July 9 through September 24, 2021, the Company issued 838,195 1,800,000 Common and Preferred Stock Issuances - 2020 The Company in January 2020 paid $ 50,000 100,000 In January 2020, the Company converted 435,990 In March 2020, the Company entered into agreements to issue 4,640,000 125,280 2,320,000 two years .045 1,243 In March 2020, certain holders of convertible promissory notes entered into agreements to exchange certain notes totaling $ 526,113 425,000 23,430 77,683 19,485,668 2,200,000 two-year term 0.045 4,400,000 .045 March 31, 2022

COMMON STOCK OPTIONS, WARRANTS

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	9 Months Ended
	Sep. 30, 2021
Common Stock Options Warrants And Restricted Stock Units
COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	NOTE 6: COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Common Stock Options The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests. The following schedule summarizes the changes in the Company’s stock options: SCHEDULE OF CHANGES IN STOCK OPTION Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2020 28,885,461 $  0.024 120.00 5.57 $ 1,661,429 $ 0.05 Options granted - $ - - $ - Options exercised (2,500,000 ) $ - - $ - Options expired/canceled (24,132,652 ) $ - - - $ - Balance at September 30, 2021 2,252,809 $  0.024 0.04 7.95 $ 191,301 $ 0.04 Exercisable at September 30, 2021 2,252,809 $ 0.024 0.04 7.95 $ 191,301 $ 0.04 During the nine months ended September 30, 2021, the Company’s CEO exercised 2,500,000 24,120,152 12,500 During the nine months ended September 30, 2021 and 2020, the Company recognized $ 0 2,176 Common Stock Warrants The following schedule summarizes the changes in the Company’s stock warrants: SCHEDULE OF CHANGES IN STOCK WARRANTS Warrants Outstanding Weighted Weighted Number Of Shares Exercise Price Per Share Average Remaining Contractual Life Aggregate Intrinsic Value Average Exercise Price Per Share Balance at December 31, 2020 32,064,375 $ 0.04 80.00 1.65 $ 1,614,567 $ 0.06 Warrants granted 11,237,500 $ 0.10 - $ - Warrants exercised (7,230,000 ) $ - - $ Warrants expired/cancelled (709,375 ) $ - - - $ Balance at September 30, 2021 35,362,500 $ 0.04 0.10 1.22 $ 1,829,923 $ 0.07 Exercisable at September 30, 2021 35,362,500 $ 0.04 0.10 1.22 $ 1,829,923 $ 0.07 Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows: SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT Nine Months Ended Year Ended September 30, 2021 December 31, 2020 Expected term - 2 5 Expected volatility - % 109 147 % Expected dividend yield - - Risk-free interest rate - % 0.20 0.58 % The Company issued a convertible note in the amount of $ 100,000 8 June 30, 2020 1,250,000 0.06 two years 1,312,500 .06 March 31, 2022 28,482 In March through June 2020, the Company entered into agreements to issue 18,440,000 497,880 9,220,000 two years .045 8,143 In March through June 2020, certain holders of convertible promissory notes entered into agreements to exchange certain notes totaling $ 651,044 525,000 27,536 98,508 21,770,668 2,200,000 two-year term 0.045 4,400,000 .045 March 31, 2022 77,883 Between November 30, 2020 and December 2, 2020 the Company sold 19,200,000 19,200 0.06 On November 30, 2020, the Company exchanged 1,867,500 933,750 6,860,000 4,759,435 In the Company’s quarter ended December 31, 2020, 22,364,972 Between January 8, 2021 and January 29, 2021, the Company issued 3,870,428 5,430,000 In March 2021 the Company sold 11,237,500 11,238 0.10 From July 9 through September 24, 2021, the Company issued 838,195 1,800,000 In the nine months ended September 30, 2021, 709,375 Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units: SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2020 262,500 $ 0.59 RSU’s granted 42,700,000 $ 0.08 RSU’s vested (17,700,000 ) $ - RSU’s forfeited - $ - Balance at September 30, 2021 25,262,500 $ 0.08 During the nine months ended September 30, 2021 and 2020, the Company recognized $ 1,614,000 0 2,405,400 On May 3, 2021, the Company has granted 12,000,000 700,000 12,000,000 On May 3, 2021, as part of an Employment Agreement with the CEO, the Company granted 30,000,000 30,000,000 15,000,000 5,000,000 5,000,000 5,000,000 15,000,000 5,000,000

COMMITMENT

COMMITMENT	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT	NOTE 7: COMMITMENT On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023. Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $ 225,000 7,500

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8: SUBSEQUENT EVENTS In October, 2021, the Company issued 2,005,693 3,500,000

BASIS OF PRESENTATION AND SIG_2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Business Overview	Business Overview The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“ SMSC 950,000,000 0.001 20,000,000 0.001 Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel ™ In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel ™ FDA ® Based on the FDA’s recommendation, RadioGel ™ ® ® ® ™ ® ™ ® ™” ® ®
IsoPet Solutions	IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet ® ® The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet ® ® The effectiveness of IsoPet ® ® The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel ™ ® ® Commencing in July 2019, the Company recognized its first commercial sale of IsoPet ® ® Our plan is to incorporate the data assembled from our work with Isopet ® ™ FDA ™ ™ ™ Y-90 half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days Recently, the Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication. The Company’s lead brachytherapy products, including RadioGel ™ Battelle ™ Battelle License The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet ® ™
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $ 2 The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019. The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for 50,000,000 0.10 5,000,000 The Company’s initial Regulation A+ raised approximately $ 4,000,000 For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents. ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist new regional clinics with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $ 2 the next 12 to 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel ™ Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States, the initial epicenter of the COVID-19 outbreak in the United States. The Company has started to in recent weeks to continue their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. As of September 30, 2021, the Company has $ 1,986,591 There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2021 and December 31, 2020, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.
Derivative Liabilities and Beneficial Conversion Feature	Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.
Fixed Assets	Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $ 2,500 1,500 Depreciation is computed using the straight-line method over the following estimated useful lives: SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE Production equipment: 3 7 Office equipment: 2 5 Furniture and fixtures: 2 5 Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.
License Fees	License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel ™ 17,500 the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%) Future minimum royalties for the years ending December 31 are noted below: SCHEDULE OF FUTURE MINIMUM ROYALTIES Sep 30, 2021 Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2021 fee was paid in December 2020.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10 The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the nine months ended September 30, 2021 or years ended December 31, 2020 and 2019, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet ®
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue recognized in the nine months ended September 30, 2021 and 2020 relate to consulting income with respect to the IsoPet ®
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2021 and 2020, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of September 30, 2021 and December 31, 2020, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE September 30, 2021 December 31, 2020 Convertible debt 2,492 1,252,456 Preferred stock 12,863,195 12,988,195 Common stock options 2,252,809 28,885,461 Common stock warrants 35,362,500 32,064,375 Total potential dilutive securities 50,480,996 75,190,487
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $ 227,154 31,809
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the nine months ended September 30, 2021 and 2020, the Company incurred no
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2021 and December 31, 2020.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine months ended September 30, 2021 and 2020. The Company did not have any deferred tax liability or asset on its balance sheet on September 30, 2021 and December 31, 2020. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine months ended September 30, 2021 and 2020, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the impact that this new guidance will have on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

BASIS OF PRESENTATION AND SIG_3

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE	Depreciation is computed using the straight-line method over the following estimated useful lives: SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE Production equipment: 3 7 Office equipment: 2 5 Furniture and fixtures: 2 5
SCHEDULE OF FUTURE MINIMUM ROYALTIES	Future minimum royalties for the years ending December 31 are noted below: SCHEDULE OF FUTURE MINIMUM ROYALTIES Sep 30, 2021 Minimum Royalties per Calendar Year Calendar Year 2021 $ 10,000 2022 4,000 Total $ 14,000
SCHEDULE OF DILUTIVE EARNINGS PER SHARE	The following represent common stock equivalents that could be dilutive in the future as of September 30, 2021 and December 31, 2020, which include the following: SCHEDULE OF DILUTIVE EARNINGS PER SHARE September 30, 2021 December 31, 2020 Convertible debt 2,492 1,252,456 Preferred stock 12,863,195 12,988,195 Common stock options 2,252,809 28,885,461 Common stock warrants 35,362,500 32,064,375 Total potential dilutive securities 50,480,996 75,190,487

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
SCHEDULE OF RELATED PARTY TRANSACTION	As of September 30, 2021 and December 31, 2020, the Company had the following related party notes outstanding: SCHEDULE OF RELATED PARTY TRANSACTION September 30, 2021 December 31, 2020 January 2019 $ 60,000 8 January 2020 $ 60,000 $ 60,000 March 2019 $ 48,000 8 March 2020 48,000 48,000 April 2019 $ 29,000 8 April 2020 29,000 29,000 July 2019 $ 50,000 8 July 2020 50,000 50,000 November 2019 $ 50,000 8 November 2020 50,000 50,000 Total Related Party Notes Payable, Net $ 237,000 $ 237,000

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	As of September 30, 2021 and December 31, 2020, the Company had the following convertible notes outstanding. All prior notes that have been converted into common stock or repaid prior to December 31, 2020 have been excluded from the chart: SCHEDULE OF CONVERTIBLE NOTES PAYABLE 2021 2020 July and August 2012 $ 1,060,000 4.60 12 December 2013 January 2014 $ 45,000 $ 45,000 November 2020 $ 50,000 0.04 6 May 30, 2021 - 50,000 Penalties on notes in default 13,761 12,418 $ 58,761 $ 107,418

COMMON STOCK OPTIONS, WARRANT_2

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)	9 Months Ended
	Sep. 30, 2021
Common Stock Options Warrants And Restricted Stock Units
SCHEDULE OF CHANGES IN STOCK OPTION	The following schedule summarizes the changes in the Company’s stock options: SCHEDULE OF CHANGES IN STOCK OPTION Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2020 28,885,461 $  0.024 120.00 5.57 $ 1,661,429 $ 0.05 Options granted - $ - - $ - Options exercised (2,500,000 ) $ - - $ - Options expired/canceled (24,132,652 ) $ - - - $ - Balance at September 30, 2021 2,252,809 $  0.024 0.04 7.95 $ 191,301 $ 0.04 Exercisable at September 30, 2021 2,252,809 $ 0.024 0.04 7.95 $ 191,301 $ 0.04
SCHEDULE OF CHANGES IN STOCK WARRANTS	The following schedule summarizes the changes in the Company’s stock warrants: SCHEDULE OF CHANGES IN STOCK WARRANTS Warrants Outstanding Weighted Weighted Number Of Shares Exercise Price Per Share Average Remaining Contractual Life Aggregate Intrinsic Value Average Exercise Price Per Share Balance at December 31, 2020 32,064,375 $ 0.04 80.00 1.65 $ 1,614,567 $ 0.06 Warrants granted 11,237,500 $ 0.10 - $ - Warrants exercised (7,230,000 ) $ - - $ Warrants expired/cancelled (709,375 ) $ - - - $ Balance at September 30, 2021 35,362,500 $ 0.04 0.10 1.22 $ 1,829,923 $ 0.07 Exercisable at September 30, 2021 35,362,500 $ 0.04 0.10 1.22 $ 1,829,923 $ 0.07
SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT	Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows: SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT Nine Months Ended Year Ended September 30, 2021 December 31, 2020 Expected term - 2 5 Expected volatility - % 109 147 % Expected dividend yield - - Risk-free interest rate - % 0.20 0.58 %
SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS	The following schedule summarizes the changes in the Company’s restricted stock units: SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2020 262,500 $ 0.59 RSU’s granted 42,700,000 $ 0.08 RSU’s vested (17,700,000 ) $ - RSU’s forfeited - $ - Balance at September 30, 2021 25,262,500 $ 0.08

SCHEDULE OF DEPRECIATION ESTIMA

SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE (Details)	9 Months Ended
	Sep. 30, 2021
Production Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	3 years
Production Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	7 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years

SCHEDULE OF FUTURE MINIMUM ROYA

SCHEDULE OF FUTURE MINIMUM ROYALTIES (Details)	Sep. 30, 2021USD ($)
Accounting Policies [Abstract]
2021	$ 10,000
2022	4,000
Total	$ 14,000

SCHEDULE OF DILUTIVE EARNINGS P

SCHEDULE OF DILUTIVE EARNINGS PER SHARE (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	50,480,996	75,190,487
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	2,492	1,252,456
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	12,863,195	12,988,195
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	2,252,809	28,885,461
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	35,362,500	32,064,375

BASIS OF PRESENTATION AND SIG_4

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 15, 2021	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Common stock, shares authorized		950,000,000					950,000,000			950,000,000
Common stock, par value		$ 0.001					$ 0.001			$ 0.001
Preferred stock, shares authorized		20,000,000					20,000,000		20,000,000	20,000,000
Preferred stock, par value		$ 0.001					$ 0.001			$ 0.001
Description of risk exposure							half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days
Current operation activities							$ 2,000,000
Number of shares issued	50,000,000
Price per share	$ 0.10
Number of shares issued, value	$ 5,000,000		$ 1,800,000		$ 491,010	$ 6,870
Offering term							the next 12 to 24 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.
Cash on hand		$ 1,986,591					$ 1,986,591			$ 903,704
Production costs							2,500
Other fixed assets cost							1,500
Nonrefundable license fee							$ 17,500
Royalties percentage, description							the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%)
Economic life of the patent							10 years
Research and development costs		$ 66,831		$ 14,383			$ 227,154	$ 31,809
Advertising and marketing costs							$ 0	$ 0
Significant Change in Unrecognized Tax Benefits							The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months
Maximum [Member]
Property, Plant and Equipment [Line Items]
Proceeds from stock offering							$ 4,000,000

SCHEDULE OF RELATED PARTY TRANS

SCHEDULE OF RELATED PARTY TRANSACTION (Details) (Parenthetical) - USD ($)	1 Months Ended
	Nov. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Feb. 20, 2019
Related Party Transaction [Line Items]
Debt instrument, face amount						$ 100,000
Note, interest rate						8.00%
Related Party Notes Payable [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount					$ 60,000
Note, interest rate					8.00%
Note due date, description					January 2020
Related Party Notes Payable [Member] | Related Party One [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount				$ 48,000
Note, interest rate				8.00%
Note due date, description				March 2020
Related Party Notes Payable [Member] | Related Party Two [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount			$ 29,000
Note, interest rate			8.00%
Note due date, description			April 2020
Related Party Notes Payable [Member] | Related Party Three [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount		$ 50,000
Note, interest rate		8.00%
Note due date, description		July 2020
Related Party Notes Payable [Member] | Related Party Four [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount	$ 50,000
Note, interest rate	8.00%
Note due date, description	November 2020

SCHEDULE OF RELATED PARTY TRA_2

SCHEDULE OF RELATED PARTY TRANSACTION (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	$ 237,000	$ 237,000
Related Party Notes Payable [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	60,000	60,000
Related Party Notes Payable [Member] | Related Party One [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	48,000	48,000
Related Party Notes Payable [Member] | Related Party Two [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	29,000	29,000
Related Party Notes Payable [Member] | Related Party Three [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	50,000	50,000
Related Party Notes Payable [Member] | Related Party Four [Member]
Related Party Transaction [Line Items]
Total Related Party Notes Payable, Net	$ 50,000	$ 50,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)

Jun. 28, 2021

Nov. 25, 2019

Sep. 24, 2019

Apr. 29, 2019

Mar. 27, 2019

Feb. 20, 2019

Jan. 24, 2019

Jun. 30, 2021

May 31, 2021

Jan. 31, 2021

Jan. 29, 2021

Apr. 30, 2020

Sep. 24, 2021

Jun. 30, 2021

Mar. 31, 2020

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2020

Dec. 31, 2019

Mar. 31, 2021

Dec. 02, 2020

Aug. 20, 2019

Jul. 05, 2019

Related Party Transaction [Line Items]

Debt instrument interest rate

8.00%

Note maturity date

Aug. 20, 2019

Proceeds from warrants

11,237,500

19,200,000

750,000

Notes payable to related party

$ 237,000

$ 237,000

Accrued interest payable

$ 619

Related party payables

32,110

32,110

Convertible note payable

15,000

58,761

107,418

Debt conversion, amount converted

$ 3,124

$ 50,370

$ 701,044

Debt conversion, shares issued

694,178

Number of share exercised

2,500,000

Stock options exercised

Series A Preferred Stock [Member]

Related Party Transaction [Line Items]

Cancelation of shares

100,000

Common Stock [Member]

Related Party Transaction [Line Items]

Conversion of common shares

5,449,875

Debt conversion, shares issued

1,259,250

Number of share exercised

2,500,000

3,870,428

838,195

2,125,000

Stock options exercised

$ 2,125

Cancelation of shares

375,000

375,000

Director [Member]

Related Party Transaction [Line Items]

Debt instrument interest rate

800.00%

8.00%

8.00%

8.00%

Note maturity date

Nov. 25, 2020

Jul. 5, 2020

Mar. 27, 2020

Jan. 24, 2020

Interest expenses, related party

$ 14,142

14,194

Notes payable to related party

$ 50,000

$ 29,000

$ 48,000

$ 60,000

$ 50,000

Debt term

one-year period

one-year period

one-year period

one

Accrued interest payable

$ 44,409

CEO [Member]

Related Party Transaction [Line Items]

Related party payables

$ 15,000

Chairman [Member] | April 2020 [Member]

Related Party Transaction [Line Items]

Conversion of common shares

385,302

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Number of share exercised

2,500,000

Cancelation of shares

16,000,000

8,120,152

Number of securities warrant exercise, share

150,000

Chief Executive Officer [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Number of share exercised

2,500,000

Number of securities warrant exercise, share

91,304

Convertible Notes Payable [Member]

Related Party Transaction [Line Items]

Interest expenses, related party

$ 0

$ 298

$ 321

Convertible note payable

$ 45,000

$ 45,000

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Advances from related party

20,000

Repayment of advance from related party

$ 5,000

Advances from related party, outstanding balance

$ 15,000

Debt instrument interest rate

8.00%

12.50%

Note maturity date

Jan. 15, 2020

Proceeds from warrants

150,000

Debt instrument description

The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020

Debt discount

$ 3,721

Number of share exercised

2,500,000

2,500,000

Stock options exercised

$ 60,000

$ 60,000

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) - USD ($)	Nov. 30, 2020	Aug. 31, 2012	Jul. 31, 2012	Feb. 20, 2019
Short-term Debt [Line Items]
Debt instrument, face amount				$ 100,000
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt instrument, face amount		$ 1,060,000	$ 1,060,000
Debt conversion price per share		$ 4.60	$ 4.60
Debt interest rate		12.00%	12.00%
Debt maturity date description			December 2013
Convertible Notes Payable One [Member]
Short-term Debt [Line Items]
Debt instrument, face amount	$ 50,000
Debt conversion price per share	$ 0.04
Debt interest rate	6.00%
Debt maturity date description	May 30, 2021	January 2014

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Apr. 30, 2020
Short-term Debt [Line Items]
Principal	$ 58,761	$ 107,418	$ 15,000
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Principal	45,000	45,000
Convertible Notes Payable One [Member]
Short-term Debt [Line Items]
Principal		50,000
Convertible Notes Payable on Penalties [Member]
Short-term Debt [Line Items]
Principal	$ 13,761	$ 12,418

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Nov. 30, 2020	Feb. 20, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 15, 2021	Dec. 31, 2020	Apr. 30, 2020
Short-term Debt [Line Items]
Convertible note payable			$ 58,761			$ 107,418	$ 15,000
Debt maturity date		Aug. 20, 2019
Debt instrument interest rate		8.00%
Proceeds from convertible debt				$ 100,000
Price per share					$ 0.10
Convertible Promissory Note [Member]
Short-term Debt [Line Items]
Convertible note payable	$ 50,000
Debt instrument interest rate	6.00%
Conversion price per share	$ 0.04
Warrant exchange shares	1,867,500
Conversion of common shares	933,750
Convertible Promissory Note [Member] | Qualified Financing [Member]
Short-term Debt [Line Items]
Debt maturity date	May 30, 2021
Proceeds from convertible debt	$ 350,000
Convertible Promissory Note [Member] | Qualified Financing [Member] | Note Holders [Member]
Short-term Debt [Line Items]
Price per share	$ 1.20
Warrant exchange shares	1,867,500
Conversion of common shares	933,750
Convertible Note Payable [Member]
Short-term Debt [Line Items]
Interest expenses			$ 4,028	$ 19,783

PROMISSORY NOTES PAYABLE (Detai

PROMISSORY NOTES PAYABLE (Details Narrative) - USD ($)	Jul. 14, 2020	Aug. 20, 2019	Feb. 20, 2019	Apr. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021	Dec. 02, 2020
Schedule of Capitalization, Long-term Debt [Line Items]
Debt instrument, face amount			$ 100,000
Debt maturity date			Aug. 20, 2019
Debt instrument interest rate			8.00%
Number of warrants issued		750,000							11,237,500	19,200,000
Interest expense					$ 6,577	$ 7,151	$ 19,628	$ 280,642
Repayment of notes payable								50,000
Accrued interest payable				$ 619
Debt conversion, amount converted				$ 3,124			$ 50,370	701,044
Debt instrument converted into shares of common stock				694,178
Two Noteholders [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt maturity date		Aug. 20, 2020
Two Noteholders [Member] | Minimum [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt instrument, interest rate increase		8.00%
Two Noteholders [Member] | Maximum [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt instrument, interest rate increase		15.00%
Noteholders One [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Number of warrants issued		375,000
Noteholders Two [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Number of warrants issued		375,000
Promissory Notes One [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt instrument, face amount			$ 50,000
Promissory Notes Two [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Debt instrument, face amount			$ 50,000
Promissory Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Number of warrants issued					1,250,000		1,250,000
Fair value of warrants debt discount					$ 28,721		$ 28,721
Interest expense							$ 0	$ 8,032
Repayment of notes payable	$ 50,000
Accrued interest payable	13,442
Debt conversion, amount converted	$ 50,000
Debt instrument converted into shares of common stock	1,851,852

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Sep. 15, 2021	Jun. 28, 2021	Dec. 28, 2020	Nov. 30, 2020	Mar. 28, 2019	Jun. 30, 2021	May 31, 2021	Mar. 31, 2021	Jan. 31, 2021	Jan. 29, 2021	Apr. 30, 2020	Mar. 31, 2020	Jan. 31, 2020	Mar. 31, 2019	Oct. 31, 2018	Jun. 30, 2015	Sep. 30, 2021	Sep. 24, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 02, 2020	Mar. 27, 2019	Oct. 08, 2018	Mar. 31, 2016
Class of Stock [Line Items]
Common stock shares authorized																	950,000,000								950,000,000		950,000,000
Common stock par value																	$ 0.001								$ 0.001		$ 0.001
Common stock shares issued																	335,775,389								335,775,389		292,278,591
Common stock shares outstanding																	335,775,389								335,775,389		292,278,591
Preferred stock shares authorized						20,000,000											20,000,000		20,000,000						20,000,000		20,000,000
Preferred stock par value																	$ 0.001								$ 0.001		$ 0.001
Number of shares issued	50,000,000
Number of shares issued, value	$ 5,000,000																			$ 1,800,000		$ 491,010	$ 6,870
Debt conversion, share											694,178
Debt instrument, accrued interest									$ 50,370
Gain (Loss) on Extinguishment of Debt																									$ 176,295
Proceeds from issuance of common stock								$ 1,800,000
Warrant purchase								$ 11,238												$ 11,238
Number of share exercised																									2,500,000
Fair value of vested shares																			$ 1,614,000
Warrant exercise price								$ 0.10												$ 0.10								$ 0.06
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Conversion price per share				$ 0.04
Conversion of common shares				933,750
Convertible Promissory Note [Member] | Note Agreement [Member]
Class of Stock [Line Items]
Number of shares issued												19,485,668
Number of shares issued, value												$ 77,683
Debt periodic payment												526,113
Debt principal amount												425,000
Debt accrued interest												$ 23,430
Convertible Promissory Note [Member] | Holders Agreement [Member]
Class of Stock [Line Items]
Number of warrants issued												2,200,000											2,200,000
Warrant exercise price												$ 0.045											$ 0.045
Warrant term description												two-year term
Convertible Promissory Note [Member] | Previously Amende Agreement [Member]
Class of Stock [Line Items]
Number of warrants issued												4,400,000											4,400,000
Warrant exercise price												$ 0.045											$ 0.045
Warrants expiration												Mar. 31, 2022											Mar. 31, 2022
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares vested						12,000,000
Fair value of vested shares						$ 1,080,000
Common Stock [Member]
Class of Stock [Line Items]
Cancelation of shares		375,000				375,000
Number of shares issued								22,500,000												22,500,000		18,440,000
Number of shares issued, value																				$ 22,500		$ 18,440
Debt conversion, share									1,259,250
Number of warrants issued								11,237,500												11,237,500
Number of share exercised		2,500,000								3,870,428								838,195	2,125,000
Fair value of vested shares
Conversion of common shares																							5,449,875
Warrant [Member]
Class of Stock [Line Items]
Number of warrant exeercised										5,430,000								1,800,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued			4,759,435									4,640,000
Number of shares issued, value												$ 125,280
Number of warrants issued												2,320,000											2,320,000
Warrant terms												2 years											2 years
Warrant exercise price												$ 0.045											$ 0.045
Number of warrants issued, value												$ 1,243											$ 1,243
Common Stock [Member] | Note Agreement [Member]
Class of Stock [Line Items]
Conversion of common shares																								21,770,668
Accounts Payable [Member]
Class of Stock [Line Items]
Number of shares issued							519,480		384,445
Number of shares issued, value							$ 40,000		$ 50,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized															5,000,000		5,000,000								5,000,000		5,000,000			5,000,000
Preferred stock par value																														$ 0.001
Preferred stock, liquidation preference per share															$ 1
Conversion price per share															$ 0.08
Voting percentage															Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference
Redemption percentage															100.00%
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized														5,000,000			5,000,000								5,000,000		5,000,000		5,000,000
Preferred stock par value																													$ 0.001
Preferred stock, liquidation preference per share														$ 1
Conversion price per share														$ 0.08
Voting percentage														Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference
Redemption percentage														100.00%
Conversion of common shares													435,990
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																2,500,000	5,000,000								5,000,000		5,000,000
Preferred stock, liquidation preference per share																$ 5
Conversion price per share																$ 4
Gross proceeds from preferred stock																$ 5,000,000
Voting percentage																Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference
Redemption percentage																100.00%
Minimum [Member] | Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																															2,500,000
Maximum [Member] | Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																															5,000,000
Board of Directors [Member]
Class of Stock [Line Items]
Reverse stock split					reverse 1-for-8 stock split
Board of Directors [Member] | Minimum [Member]
Class of Stock [Line Items]
Common stock shares authorized					2,000,000,000
Board of Directors [Member] | Maximum [Member]
Class of Stock [Line Items]
Common stock shares authorized					950,000,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Cancelation of shares						16,000,000	8,120,152
Number of share exercised																									2,500,000
Chief Executive Officer [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of share exercised		2,500,000
Chief Executive Officer [Member] | Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Cancelation of shares						100,000
Investor [Member] | Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Payment to redemption of preferred stock													$ 50,000
Number of shares redeemable													100,000

SCHEDULE OF CHANGES IN STOCK OP

SCHEDULE OF CHANGES IN STOCK OPTION (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Number of Options Outstanding Beginning Balance | shares	28,885,461
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning	5 years 6 months 25 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 1,661,429
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 0.05
Number of Options granted | shares
Exercise Price Per Share granted
Weighted Average Exercise Price Per Share Options granted
Number of Options exercised | shares	(2,500,000)
Exercise Price Per Share exercised
Weighted Average Exercise Price Per Share Options exercised
Number of Options expired/cancelled | shares	(24,132,652)
Exercise Price Per Share expired/cancelled
Aggregate Intrinsic Value expired/cancelled | $
Weighted Average Exercise Price Per Share Options expired/cancelled
Number of Options Outstanding Ending Balance | shares	2,252,809
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending	7 years 11 months 12 days
Aggregate Intrinsic Value Outstanding Ending | $	$ 191,301
Weighted Average Exercise Price Per Share Outstanding Ending	$ 0.04
Number of Options Exercisable | shares	2,252,809
Weighted Average Remaining Contractual Life (in years) Exercisable	7 years 11 months 12 days
Aggregate Intrinsic Value Exercisable | $	$ 191,301
Weighted Average Exercise Price Per Share Exercisable	$ 0.04
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	0.024
Exercise Price Per Share Outstanding Ending Balance	0.024
Exercise Price Per Share Exercisable	0.024
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	120
Exercise Price Per Share Outstanding Ending Balance	0.04
Exercise Price Per Share Exercisable	$ 0.04

SCHEDULE OF CHANGES IN STOCK WA

SCHEDULE OF CHANGES IN STOCK WARRANTS (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Warrants expired/cancelled | shares	(709,375)
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Warrants Outstanding Beginning | shares	32,064,375
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	1 year 7 months 24 days
Aggregate Intrinsic Value Outstanding Beginning | $	$ 1,614,567
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 0.06
Number of Shares, Warrants granted | shares	11,237,500
Exercise Price Per Share Warrants granted	$ 0.10
Weighted Average Exercise Price Per Share Exercise Price Warrants granted
Number of Shares, Warrants exercised | shares	(7,230,000)
Exercise Price Per Share Warrants exercised
Number of Shares, Warrants expired/cancelled | shares	(709,375)
Exercise Price Per Share Warrants expired/cancelled
Aggregate Intrinsic Value warrants expired/cancelled | $
Number of Shares, Warrants Outstanding Ending | shares	35,362,500
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	1 year 2 months 19 days
Aggregate Intrinsic Value Outstanding Ending | $	$ 1,829,923
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	$ 0.07
Number of Shares, Warrants Exercisable Ending | shares	35,362,500
Weighted Average Remaining Contractual Life Warrants Exercisable	1 year 2 months 19 days
Aggregate Intrinsic Value Exercisable | $	$ 1,829,923
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	$ 0.07
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.04
Exercise Price Per Share Warrants Outstanding Ending	0.04
Exercise Price Per Share Exercisable	0.04
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	80
Exercise Price Per Share Warrants Outstanding Ending	0.10
Exercise Price Per Share Exercisable	$ 0.10

SCHEDULE OF ASSUMPTIONS USED IN

SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Expected term
Expected volatility
Expected dividend yield
Risk-free interest rate
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Expected term		2 years
Expected volatility		109.00%
Risk-free interest rate		0.20%
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Expected term		5 years
Expected volatility		147.00%
Risk-free interest rate		0.58%

SCHEDULE OF CHANGES IN RESTRICT

SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS (Details) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, RSU's Outstanding Beginning | shares	262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning | $ / shares	$ 0.59
Number of Shares, RSU's Granted | shares	42,700,000
Weighted Average Grant Date Fair Value, RSU's Granted | $ / shares	$ 0.08
Number of Shares, RSU's Vested | shares	(17,700,000)
Weighted Average Grant Date Fair Value, RSU's Vested | $ / shares
Number of Shares, RSU's Forfeited | shares
Weighted Average Grant Date Fair Value, RSU's Forfeited | $ / shares
Number of Shares, RSU's Outstanding Ending | shares	25,262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending | $ / shares	$ 0.08

COMMON STOCK OPTIONS, WARRANT_3

COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)	Sep. 15, 2021	Jun. 28, 2021	May 03, 2021	Dec. 28, 2020	Dec. 02, 2020	Nov. 30, 2020	Feb. 20, 2019	Jun. 30, 2021	Mar. 31, 2021	Jan. 29, 2021	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 24, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Apr. 30, 2020	Aug. 20, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share exercised																						2,500,000
Number of option expired																						24,132,652
Stock based compensation																						$ 1,614,000	$ 2,176
Debt instrument, face amount							$ 100,000
Debt instrument, interest rate							8.00%
Debt instrument, maturity date							Aug. 20, 2019
Number of warrants issued					19,200,000				11,237,500							11,237,500									750,000
Warrants exercise price					$ 0.06				$ 0.10							$ 0.10
Number of shares issued	50,000,000
Number of shares issued, value	$ 5,000,000															$ 1,800,000			$ 491,010	$ 6,870
Accrued interest																								$ 619
Stock issued during the period converted
Proceeds from issuance of additional warrant expenses																						$ 77,883
Proceeds from issuance of warrant					$ 19,200				$ 11,238
Warrants expired																						709,375
Restricted stock unit vesting																						$ 1,614,000	$ 0
Restricted stock expenses yet to be recognized																						$ 2,405,400
Convertible Note Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price											$ 0.045							$ 0.045	$ 0.045		$ 0.045		$ 0.045
Warrants term description											two-year term
Regulation A Plus [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price													$ 0.045									$ 0.045
Warrant term											2 years								2 years		2 years
Number of shares issued																					18,440,000
Number of shares issued, value																					$ 497,880
Number of warrants granted																					9,220,000
Warrants purchase price																					$ 8,143
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares unit granted			12,000,000
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares unit granted			30,000,000
Number of restricted shares unit vested			15,000,000
Number of shares grant date			5,000,000
Remaining RSUs vested as performance based grants			15,000,000
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares grant date			5,000,000
Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares grant date			5,000,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right exchange				6,860,000
Warrants expired																	22,364,972
Number of warrant exeercised										5,430,000				1,800,000
Warrant [Member] | Convertible Note Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument, maturity date																					Mar. 31, 2022
Number of warrants granted																					4,400,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price												$ 0.045								$ 0.045
Warrant term												2 years								2 years
Number of shares issued				4,759,435								4,640,000
Number of shares issued, value												$ 125,280
Common Stock [Member] | Note Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued											2,200,000								2,200,000		2,200,000
Stock issued during the period converted																					$ 98,508
Conversion of common shares																					21,770,668
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share exercised		2,500,000								3,870,428				838,195	2,125,000
Number of shares issued									22,500,000							22,500,000			18,440,000
Number of shares issued, value																$ 22,500			$ 18,440
Stock issued during the period converted																				$ 5,449
Conversion of common shares																				5,449,875
Convertible Promissory Note [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument, face amount											$ 525,000								525,000		$ 525,000
Debt instrument, interest rate						6.00%
Convertible promissory note											651,044								651,044		651,044
Accrued interest											$ 27,536								$ 27,536		$ 27,536
Conversion of common shares						933,750
Class of warrant or right exchange						1,867,500
Convertible Promissory Note [Member] | Note Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued												19,485,668
Number of shares issued, value												$ 77,683
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation																						$ 0	$ 2,176
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share exercised																						2,500,000
Number of stock option rescinded																						24,120,152
Number of option expired																						12,500
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares unit granted			30,000,000
Chief Executive Officer [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share exercised		2,500,000
Accredited Investors [Member] | Convertible Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt instrument, face amount													$ 100,000									$ 100,000
Debt instrument, interest rate													8.00%									8.00%
Debt instrument, maturity date																						Jun. 30, 2020
Number of warrants issued													1,250,000									1,250,000
Warrants exercise price													$ 0.06									$ 0.06
Warrant term													2 years									2 years
Warrants issued for extension of notes payable																						$ 28,482
Accredited Investors [Member] | Convertible Notes [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued													1,312,500									1,312,500
Warrants exercise price													$ 0.06									$ 0.06
Warrant expiration date													Mar. 31, 2022									Mar. 31, 2022
Consultants [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted shares unit granted			700,000
One Consultants [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued								12,000,000
Board of Directors [Member] | Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares grant date			5,000,000

COMMITMENT (Details Narrative)

COMMITMENT (Details Narrative) - Employment Agreement [Member] - Dr. Michael K. Korenko [Member]	Jun. 04, 2019USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term description	The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023.
Compensation amount	$ 225,000
Discretionary bonus	$ 7,500

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - shares	Jun. 28, 2021	Oct. 31, 2021	Jan. 29, 2021	Sep. 24, 2021	Jun. 30, 2021	Sep. 30, 2021
Subsequent Event [Line Items]
Number of share exercised						2,500,000
Common Stock [Member]
Subsequent Event [Line Items]
Number of share exercised	2,500,000		3,870,428	838,195	2,125,000
Warrant [Member]
Subsequent Event [Line Items]
Number of warrant exeercised			5,430,000	1,800,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of share exercised		2,005,693
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Number of warrant exeercised		3,500,000